Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2021-01-20
Target enrollment:
Participant gender:
Summary
Determine the maximum tolerated dose (MTD) and toxicity profile of the combination of
cyclophosphamide and ATO (Arsenic Trioxide) in subjects with relapsed refractory AML.
Determine the efficacy of ATO and cyclophosphamide in this population, as defined by response
rate, response duration, event-free survival (EFS) and overall survival (OS).
Determine the number of transplant-eligible subjects who are successfully bridged to stem
cell transplantation or donor lymphocyte infusion.